Valye reports for unlimited access

ModuLink Inc. is a holding company incorporated in Nevada, conducting business through subsidiaries primarily in Hong Kong, Australia, and the British Virgin Islands. Its core business is property development using modular integrated construction technology (MiC), enhanced by proprietary air-to-water (A2W) technology and IoT-enabled property management systems. The company aims to develop sustainable, smart, and energy-efficient communities across multiple continents. Its subsidiaries cover strategic planning, design and engineering, technology development, and project management. ModuLink completed the acquisition of a 60% stake in ASA Robotics Limited, a robotics and AI solutions company, in April 2026, integrating advanced automation technologies into its portfolio. The company finances operations through equity issuances, debt, and support from officers and directors, with noted liquidity challenges as of Q1 2026.

urban-gro, Inc. was founded in 2014 and transitioned from a Colorado-based design-build firm focused on Controlled Environment Agriculture (CEA) to a Delaware corporation trading on NASDAQ under the ticker UGRO. In 2026, the company completed a reverse merger with Flash Sports & Media, Inc., shifting its business focus to sports, media, and experiential marketing. The merger incorporated IPG's cricket commercialization business, including exclusive rights to the Lanka Premier League. Prior to the merger, urban-gro's revenue was derived from equipment systems sales, construction design-build contracts, and services, with the latter two segments discontinued or wound down in 2025. The company recognizes revenue based on transfer of control for equipment and over time for construction contracts, applying significant judgment in revenue recognition. Financially, the company has experienced recurring losses, a net capital deficiency, and liquidity constraints, with a current ratio of 0.05 as of March 31, 2026. The company has relied on dilutive financing and faces risks related to integration, seasonality, foreign currency exposure, and regulatory environments in Sri Lanka and the UAE.

MGSD operates through its subsidiary Tongzhilian, headquartered in Beijing, China, providing cultural tourism services including education and family tours, distributing Chinese cultural and creative products, and planning to expand into arts expositions. The company designs tours with cultural content, cooperates with third-party operators for logistics, and markets through a network of sales agents. Product sales include tea, alcohol, gift cards, and plans for proprietary cultural product lines targeting youth markets. Arts expositions involve participatory cultural presentations marketed similarly to tours. MGSD holds necessary operating licenses in Beijing and emphasizes multiple service and product offerings, leveraging the CEO's extensive marketing experience and social network. The company faces a highly competitive market with various cultural tourism and product providers. Seasonality affects tourism and exposition sales but not product sales. MGSD does not maintain insurance for property or liability risks. Financially, the company reported a net loss and limited revenue as of Q2 2026, with liquidity challenges indicated by a current ratio below 1. MGSD has engaged in strategic agreements to integrate educational technology and intangible cultural heritage resources into its offerings [S1][S2][S16][S18].

Alibaba Group Holding Ltd is a major player in the Internet Retail industry, operating primarily in the Consumer Cyclical sector. The company reported $148.4 billion in revenue and $15.0 billion in net income for the fiscal year ending March 31, 2026. Its liquidity position as of that date shows a current ratio of 1.28 and a cash ratio of 0.29, indicating moderate short-term financial flexibility. Alibaba's business model includes significant investments in technology, particularly in AI and cloud computing, which are key focus areas in recent public discourse. The company faces competitive pressures but maintains a strong market presence and ongoing innovation initiatives.

X3 Acquisition Corp. Ltd. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business purpose is to identify and complete an initial business combination with one or more target companies, primarily focusing on the financial services industry but remaining open to other sectors. The company completed its IPO in January 2026, issuing units consisting of Class A ordinary shares and redeemable warrants, raising gross proceeds of $225 million including over-allotment and private placement warrants. These proceeds are held in a trust account invested in low-risk instruments. The company has no operating history or revenue and is classified as a shell company. Its management team has extensive experience in financial services and capital markets. The company plans to conduct thorough due diligence on potential targets and aims to complete a business combination within 24 months of the IPO, subject to possible extension. If unsuccessful, it will redeem public shares and liquidate.

Capstone Holding Corp. is a publicly traded company on Nasdaq (ticker CAPS) operating primarily through its consolidated subsidiary TotalStone, LLC, which manufactures and sells stone products. The company maintains inventories valued at the lower of cost or net realizable value, with reserves for obsolete inventory. Its asset base includes property, equipment, goodwill, and intangible assets. The company has reported consistent net losses in recent years, with a negative equity position as of the end of 2024. Liquidity metrics as of Q1 2026 show current liabilities slightly exceeding current assets and minimal cash on hand. The company has outstanding debt including convertible notes, some of which have been converted into common stock, causing dilution. It also has related party management fee arrangements with Brookstone Partners IAC. The company faces regulatory risks related to Nasdaq listing standards and financial covenant compliance.

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for autoimmune diseases by targeting the neonatal fragment crystallizable receptor (FcRn) to reduce pathogenic IgG antibodies. Its lead product candidate, IMVT-1402, is designed to achieve deep IgG reductions with a favorable safety profile and convenient administration via a self-injector. The company is conducting multiple potentially registrational clinical trials across six autoimmune indications, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and a proof-of-concept trial in cutaneous lupus erythematosus. Immunovant previously developed batoclimab, a first-generation FcRn inhibitor, but discontinued its development after Phase 3 thyroid eye disease trials failed to meet primary endpoints. The company relies on a license agreement with HanAll Biopharma for intellectual property rights and has significant cash reserves to fund ongoing clinical development. It has not generated revenue and continues to incur operating losses.

Analog Devices Inc is a semiconductor company operating globally with a diversified product portfolio serving Industrial, Automotive, Communications, and Consumer markets. The company sells through multiple channels including distributors and direct customers. Recent financial results show strong revenue growth driven by increased demand across all end markets, particularly in AI infrastructure and aerospace and defense. The company maintains solid profitability and liquidity, with ongoing strategic initiatives including a global repositioning program and acquisitions to enhance its AI capabilities.

Roivant Sciences Ltd. is a biopharmaceutical company incorporated in Bermuda with principal offices in London, New York, and Basel. It is publicly traded on Nasdaq under the ticker ROIV. The company focuses on developing innovative therapies, as evidenced by its clinical trial activities and patent portfolio. Roivant reported strong liquidity as of March 31, 2026, with over $4 billion in cash, cash equivalents, and short-term investments, and maintains an active share repurchase program. The company recently settled patent litigation with Moderna related to lipid nanoparticle technology used in vaccines, involving significant payments and licensing agreements. Roivant has reported net losses in recent periods, reflecting ongoing investment in development activities.

Haemonetics Corporation develops and markets medical technologies aimed at improving healthcare quality and efficiency. The company operates through three main segments: Plasma, Blood Center, and Hospital. The Plasma segment provides automated plasma collection devices, disposables, and software solutions to optimize plasma collection for pharmaceutical manufacturing. The Blood Center segment offers blood collection and processing devices for plasma, red cells, and platelets, focusing on donor safety and operational efficiency. The Hospital segment includes Interventional Technologies (vascular closure devices, sensor-guided technologies, esophageal protection) and Blood Management Technologies (hemostasis management, cell salvage, transfusion management) designed to improve patient outcomes and reduce hospital costs. Haemonetics sells products globally through direct sales and distributors, with a significant portion of revenue concentrated among top customers. The company invests in research and development to innovate and enhance its product portfolio and holds numerous patents and trademarks to protect its intellectual property [S1].

CAVA Group, Inc. is a Delaware corporation formed in 2015, operating a fast-casual Mediterranean restaurant chain with 439 restaurants across 28 states and Washington, D.C. as of December 28, 2025. The company offers chef-curated and customizable bowls and pitas, with a menu designed to accommodate a wide range of dietary preferences. CAVA centrally produces dips, spreads, and dressings for its restaurants and sells these products in grocery stores. The company aims to expand its footprint to over 1,000 restaurants in the U.S. by 2032, leveraging trends in authentic ethnic cuisine, health and wellness, and convenience. It employs approximately 13,480 team members and emphasizes a strong culture and talent development programs. CAVA uses a data-driven approach to site selection and flexible restaurant designs, including digital ordering and drive-thru options. The company has vertically integrated manufacturing and a directly sourced supply chain with over 50 trusted partners. Recent financial disclosures show solid liquidity and profitability metrics for Q1 2026. The company faces competition from various foodservice and retail channels and operational risks related to growth and supply chain management [S1][S2].

American Resources Corp (ARC) is a diversified natural resources company headquartered in Fishers, Indiana. It operates through subsidiaries including American Infrastructure Corporation (AIC), which manages six coal mining and processing operations in the Central Appalachian and Illinois coal basins, and Electrified Materials Corporation (EMC), focused on recovered metal and steel aggregation and sales. ARC also owns ReElement Technologies LLC, a company specializing in purification and monetization of critical and rare earth elements and end-of-life magnets and batteries. ARC's coal products include metallurgical coal for steelmaking, pulverized coal injections, and high-BTU, low sulfur bituminous coal for industrial uses. The company competes domestically and internationally in coal and critical minerals markets against companies such as MP Materials and Arch Resources. ARC reported a net income of $55.4 million for 2025 despite zero revenue reported, reflecting non-operational gains or accounting factors. The company maintains a strong liquidity position with a current ratio of 2.19 as of year-end 2025.

Cyber Enviro-Tech, Inc. (CETI) is a Wyoming-based water science technology company founded in 1986, specializing in remediation of contaminated industrial wastewater with an initial focus on the oil & gas industry. The company integrates advanced technologies such as cyber, aerospace, satellite, and AI telemetry into its water filtration and alternative energy systems. CETI's pilot project was an oil field in West Texas, which was spun off in 2025 to focus on water and soil remediation technologies. CETI also held a majority stake in CETI Axenic, a water remediation company for commercial laundry, which ceased operations at the end of 2025. The company currently has no employees but engages consultants and pursues partnerships to shorten sales cycles. CETI aims to address water contamination issues globally, with potential applications in the Middle East, meat packing industry, and municipalities. Financially, CETI reported no revenue and a net loss of $7.64 million for 2025, with liquidity ratios indicating limited short-term financial strength. The company has entered into an equity purchase agreement to raise up to $30 million in capital.

Newton Golf Company, Inc. develops and sells premium golf equipment, including technology-driven golf shafts and putters designed to enhance player performance. The company emphasizes domestic manufacturing and assembly to maintain quality and operational flexibility. Its Newton Motion™ shaft product line, including the Fast Motion driver shaft, is a key growth driver. The company distributes products through multiple channels, including direct-to-consumer e-commerce, professional club fitters, and retail partners, with a primary focus on the U.S. market and select international markets such as Japan and South Korea. Newton Golf invests in marketing and professional endorsements to build brand awareness and expand market penetration. The company has completed multiple public offerings and corporate restructuring events, including reverse stock splits, to support its growth strategy.

BioRestorative Therapies, Inc. develops cell and tissue-based therapeutic products using adult stem cells. The company’s primary focus is on its Disc/Spine Program, with BRTX-100 as the lead investigational product designed for non-surgical treatment of chronic lower back pain arising from degenerative disc disease. BRTX-100 is an autologous mesenchymal stem cell product cultured under hypoxic conditions to enhance cell viability and is administered via injection into the damaged disc. The company is conducting a Phase 2 clinical trial with 99 patients enrolled and has FDA clearance for additional indications. BioRestorative also develops the ThermoStem Program targeting metabolic disorders using brown adipose derived stem cells and operates a commercial biocosmeceutical platform producing a proprietary cell-based serum for cosmetic use. The company has licensed a curved needle delivery device pending regulatory approval. BioRestorative has not generated significant revenues and funds operations through equity offerings and warrant exercises. As of March 31, 2026, the company held $3.1 million in cash and equivalents and reported a net loss of $2.15 million for the quarter.

Cenntro Inc. operates as a holding company with subsidiaries engaged in the design, manufacture, distribution, and servicing of electric and hydrogen-powered commercial vehicles. The company offers multiple vehicle series including Metro®, Logistar™, iChassis™, Avantier™, Teemak™, Bison Motor™, and Antric One. It employs an asset-light, distributed manufacturing model producing vehicle kits primarily in China for local assembly globally, supplemented by OEM partnerships. The company has developed a programmable smart chassis platform (iChassis™) for autonomous vehicle applications and is expanding into hydrogen-powered heavy-duty vehicles. Distribution has evolved from reliance on third-party channel partners to a hybrid model combining company-operated EV Centers, local dealer networks, and channel partners tailored to regional market conditions. Cenntro supports its distribution with a cloud-based parts distribution system and maintains warehouses in China, Spain, and the US. The company operates globally with subsidiaries in the US, Australia, Europe, Mexico, Hong Kong, Dominican Republic, and China. Financially, Cenntro reported a net loss and negative EPS for Q1 2026, with liquidity ratios indicating moderate short-term financial stability. The company faces competitive market dynamics, regulatory and legal risks, and challenges related to capital requirements and supply chain localization.

Autolus Therapeutics plc develops and commercializes programmed T cell therapies using proprietary modular technologies to engineer targeted and controlled CAR T cell products. The company’s lead product, AUCATZYL (obe-cel), is approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the US and UK, with commercial launches in both markets. The company’s pipeline includes programs targeting hematological cancers, solid tumors, and autoimmune diseases such as lupus nephritis and multiple sclerosis. Autolus employs advanced targeting technologies including fast off-rate CARs, dual-targeting CARs, and pharmacological safety switches to enhance efficacy and safety. Manufacturing is conducted at the Nucleus facility in the UK, with commercial distribution partnerships in the US. The company has incurred significant operating losses since inception and continues to invest heavily in clinical development and commercialization activities.

AleAnna, Inc. operates primarily in Italy, focusing on delivering natural gas supplies to Europe through onshore conventional natural gas exploration and renewable natural gas development. The company holds a significant working interest in the Longanesi field, one of Italy's largest modern natural gas discoveries, and owns additional conventional natural gas properties and exploration prospects supported by proprietary 3D seismic imaging. AleAnna has developed a renewable natural gas business targeting carbon negative biomethane production from agricultural waste, acquiring several biogas plants in Italy. The company is headquartered in Dallas, Texas, with offices in Rome and Milan, and is listed on NASDAQ under the ticker ANNA following a business combination in December 2024.

Fortress Biotech, Inc. is a biopharmaceutical company that operates through a network of subsidiaries and partner companies engaged in the development and commercialization of pharmaceutical products across various therapeutic areas. The company supports its subsidiaries with business, scientific, regulatory, legal, and financial expertise to advance product candidates and commercial products. Key subsidiaries include Journey Medical Corporation, Mustang Bio, Avenue Therapeutics, and Cyprium Therapeutics, among others. Fortress Biotech’s revenue is primarily generated through its subsidiaries’ product sales and collaboration agreements. The company’s business model includes strategic licensing, milestone payments, and equity financings to fund research and development and commercialization efforts. Fortress Biotech also manages debt facilities and maintains liquidity to support ongoing operations and growth initiatives.

Trailblazer Acquisition Corp. is a Cayman Islands exempted blank check company (SPAC) incorporated in June 2025. Its sole business purpose is to identify and complete an initial business combination with one or more target companies, primarily in the media and communications, sports and entertainment, technology, and consumer retail sectors. The company completed its IPO in September 2025, raising $275 million, which is held in a trust account to fund the business combination. The company has not yet selected a target and has no operating revenues. Its management team brings experience in operations, financing, and investing across multiple industries. The company must complete its business combination by September 2027 or liquidate and return funds to shareholders. The acquisition strategy targets companies with strong market positions, growth potential, and public market readiness.

Archimedes Tech SPAC Partners III Co. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. It completed its initial public offering in January 2026, issuing units consisting of ordinary shares and redeemable warrants. The company raised gross proceeds of $276 million, which are held in a trust account for the benefit of public shareholders. The company is classified as an emerging growth company and trades on The Nasdaq Stock Market under the symbols ARCI (ordinary shares), ARCIU (units), and ARCIW (warrants). As of March 31, 2026, the company reported strong liquidity with a current ratio of 14.84 and net income of approximately $1.57 million for the quarter. The company has undergone recent management changes with a new CEO appointed in April 2026.

Talon Capital Corp. is a Cayman Islands exempted company that went public in September 2025 through an initial public offering of units on The Nasdaq Stock Market. Each unit includes one Class A ordinary share and one-third of a redeemable warrant. The company raised gross proceeds of approximately $249 million, which are held in a trust account for the benefit of public shareholders until the completion of an initial business combination or other redemption events. The company operates under an administrative services agreement with its Sponsor, which provides office space and support services. Financial disclosures indicate the company is in an early stage with limited operational revenue but reported net income and strong liquidity as of the first quarter of 2026. Risk factors are disclosed primarily through the IPO prospectus and annual report, with no material changes reported recently.

Heartflow, Inc. operates in the healthcare technology sector, focusing on AI-driven diagnostic solutions for coronary artery disease (CAD). The company’s Heartflow Platform enhances coronary computed tomography angiography (CCTA) scans by applying advanced AI and computational fluid dynamics to create personalized 3D models of patients’ coronary arteries. This enables precise assessment of blood flow, stenosis, and plaque characteristics, which are critical for accurate diagnosis and treatment planning. Heartflow’s product suite includes Heartflow RoadMap Analysis, Heartflow FFR CT Analysis (the flagship product), Heartflow Plaque Analysis, and the upcoming Heartflow PCI Navigator. The platform is integrated into clinical workflows and reimbursed under established CPT codes, facilitating adoption. The company has a substantial data asset of over 160 million annotated CCTA images, supporting continuous algorithm improvement. Heartflow’s business model is primarily pay-per-click, billing customers when physicians order specific analyses. The company has an installed base of over 1,465 accounts in the US and is expanding its market presence. Despite strong clinical validation and guideline support, Heartflow has incurred significant net losses as it invests in growth and commercialization.

Terrestrial Energy Inc. is a holding company operating through its subsidiary Terrestrial Energy Development Inc., focused on commercializing its proprietary Integral Molten Salt Reactor (IMSR) technology, an advanced nuclear reactor design. The company completed a business combination with HCM II Acquisition Corp. in October 2025 and began trading on Nasdaq under the ticker IMSR. It participates in U.S. Department of Energy programs aimed at fast-tracking licensing and deployment of advanced nuclear reactors, including pilot projects for reactor construction and fuel production using standard assay low enriched uranium (SALEU) fuel. The company has no reported revenue for 2025, reflecting its development-stage status, and incurs significant research and development and general administrative expenses as it advances its technology and commercialization efforts.

Sutro Biopharma operates as a clinical-stage biotechnology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) for oncology indications. The company leverages its proprietary XpressCF® and XpressCF+® platforms, which enable rapid and precise protein synthesis and site-specific conjugation of cytotoxic payloads to antibodies. Sutro’s lead product candidate, STRO-004, targets tissue factor (TF) and is in Phase 1 clinical trials for multiple solid tumors. The company also has preclinical programs including STRO-006 and STRO-227, targeting integrin alpha v beta 6 and PTK7 respectively, with IND filings anticipated. Sutro has established collaborations with pharmaceutical companies such as Astellas, Merck, BMS, and EMD Serono, generating significant payments and advancing development candidates. The company’s strategy includes advancing clinical development, expanding its pipeline, and pursuing strategic partnerships to maximize value. Financially, Sutro reported a net loss in Q1 2026 but maintains strong liquidity with a current ratio above 3.0. The company faces competition from other ADC developers and established oncology therapeutics but aims to differentiate through its proprietary platform technology and homogeneous ADC products.

KinderCare Learning Companies, Inc. is a provider of childcare and early education services. The company operates centers that serve families, with revenue streams partially supported by federal, state, and local government programs offering tuition subsidies and other assistance. The business model involves managing childcare centers and delivering educational programs to children. The company faces operational risks related to government funding availability and regulatory changes. Leadership transitioned in late 2025 with the appointment of a new CEO and Chair. Financial disclosures indicate recent net losses and liquidity challenges as of early 2026. The company maintains incentive plans for employees and executives to drive performance.

Marblegate Capital Corp is a publicly traded holding company focused on the New York City regulated taxi medallion market. It operates through subsidiaries that manage a large portfolio of medallion-backed loans and operate the largest taxi fleet in NYC via Signal Taxi. The company generates revenue primarily from interest income on loans, leasing of vehicles and medallions to licensed drivers, consulting services, and fees related to loan restructuring and settlements. The business model centers on the taxi medallion as a scarce, municipally regulated asset critical to NYC's mobility infrastructure. Marblegate's operations include specialty finance and fleet operations segments, with significant recent growth in fleet operations following acquisitions and consulting agreements. The company became publicly traded on the OTCQX market in April 2025 and has incurred increased expenses related to public company status and business combination activities.

SpyGlass Pharma, Inc. focuses on developing long-acting, sustained drug delivery systems for chronic eye conditions. Its lead candidate, the BIM-IOL System, combines proprietary drug pads with an intraocular lens to deliver bimatoprost over three years, aiming to reduce intraocular pressure in patients undergoing cataract surgery who have open-angle glaucoma or ocular hypertension. The company is conducting Phase 1/2 and two registrational Phase 3 clinical trials, with enrollment expected to complete in 2027. SpyGlass Pharma has no approved products or revenues and has incurred significant losses since inception. It completed its IPO in February 2026, raising $172.5 million, and as of March 31, 2026, held $238.9 million in cash and equivalents. The company depends heavily on the success of the BIM-IOL System and faces risks related to clinical development, regulatory approval, manufacturing, intellectual property, competition, and capital requirements.

Bitcoin Infrastructure Acquisition Corp Ltd is a publicly listed company trading under the ticker BIXI. The company has not publicly disclosed detailed information about its sector, industry, or business operations in the available SEC filings. The latest quarterly filing indicates the company maintains strong liquidity and reported positive net income for the quarter ending March 31, 2026.

Synlogic, Inc. operates as a biotechnology company incorporated in Delaware with principal offices in Massachusetts. The company is governed by a four-member independent board of directors and maintains standard corporate governance policies including audit and compensation committees. As of the latest quarter ending March 31, 2026, Synlogic reported no revenue but a net income of $681,000 and holds strong liquidity positions. The company has a limited number of employees focused on strategic initiatives. Synlogic's common stock is no longer listed on Nasdaq but remains a reporting company under the Securities Exchange Act. The company has equity incentive plans in place and has engaged in strategic alternatives to enhance stockholder value.

LaFayette Acquisition Corp. is a Cayman Islands exempted special purpose acquisition company (SPAC) formed in June 2024 to effect a business combination through merger, share exchange, asset acquisition, or similar transaction. The company completed its IPO on October 27, 2025, issuing 11.5 million units at $10 each, raising gross proceeds of $115 million, plus a private placement of 380,000 units raising $3.8 million. The net proceeds are held in a trust account until a business combination or liquidation event. The company has not commenced operations and currently earns interest income on trust account securities. Its management team includes experienced professionals with backgrounds in investment banking, private equity, and SPAC governance. The company intends to identify and complete a business combination with a target company that aligns with its management's expertise, focusing on companies with strong management, market readiness, sound financials, and defensible market positions, typically with enterprise values between $500 million and $1.5 billion.

Oncolytics Biotech Inc is focused on developing pelareorep, an intravenously delivered oncolytic reovirus immunotherapy that selectively infects and replicates in RAS-mutated cancer cells. Pelareorep acts by modifying the tumor microenvironment to enhance innate and adaptive immune responses, making tumors more susceptible to a range of cancer treatments including chemotherapy, checkpoint inhibitors, and other immuno-oncology agents. The company has conducted extensive clinical trials involving over 1,600 patients, showing encouraging efficacy signals in pancreatic, anal, colorectal, and breast cancers. Pelareorep is generally well tolerated with manageable side effects. The company holds a substantial patent portfolio protecting pelareorep and related technologies, with patent rights extending into the 2030s and beyond through pending applications. Oncolytics Biotech's strategy includes advancing pelareorep through clinical development, regulatory approval, and strategic partnerships, with a focus on gastrointestinal cancers. The company has not yet achieved profitability and relies on capital markets to fund operations. As of March 31, 2026, it reported cash and equivalents of $5.493 million and a current ratio of 1.38, indicating liquidity for near-term milestones but requiring additional financing for longer-term plans. The company faces competition from multiple cancer therapy modalities and depends on successful clinical, regulatory, and commercial execution.

P3 Health Partners Inc. is a Delaware-incorporated population health management company that completed a business combination in December 2021, resulting in an Up-C structure with P3 Health Partners Inc. as sole manager and partial owner of P3 Health Group, LLC. The company focuses on delivering value-based care primarily in the Medicare Advantage market, which covers approximately 34 million Medicare eligible lives in 2025. P3 contracts with health plans to provide capitated care services, receiving per-member-per-month payments and managing total cost of care to improve clinical outcomes and reduce healthcare spending. The company’s P3 Care Model emphasizes patient centricity, physician leadership, and a delegated care model that leverages local physician networks via an affiliate model, preserving physician independence and existing patient relationships. P3 supplements these partnerships with employed primary care physicians and operates clinics and wellness centers. Its proprietary technology platform integrates clinical and claims data to risk stratify patients and provide actionable insights to physicians. The company had contracted with approximately 2,400 primary care physicians as of December 31, 2025, representing less than 1% of U.S. PCPs, indicating significant market opportunity. P3’s revenue is primarily capitated revenue from at-risk contracts with health plans, with four health plans accounting for approximately 75% of total revenue in 2025. The company operates in a highly competitive and fragmented healthcare industry, facing competition from traditional fee-for-service models and other population health management companies. P3’s growth strategy includes expanding membership through current payor relationships, geographic expansion, and accretive acquisitions.

Big Digital Energy, Inc. (formerly Mawson Infrastructure Group Inc.) is a U.S.-based technology company specializing in digital infrastructure platforms. Its operations span four main business areas: Digital Colocation, AI and HPC Colocation, Energy Management, and Digital Assets Mining. The company operates data centers with a total capacity of approximately 129 MW located in the Pennsylvania-New Jersey-Maryland Interconnection Energy Market (PJM Energy Market), one of North America's largest wholesale power markets. It focuses on using carbon-free energy sources, including nuclear power, to support sustainable growth in digital economy applications. The company provides colocation services to enterprise customers, hosting specialized computing equipment for digital asset mining and AI/HPC workloads, with revenue generated through fee-based and profit-sharing agreements. It also operates its own Bitcoin mining operations and participates in energy management programs to optimize energy costs and grid stability. The company faces risks related to customer concentration, supply chain constraints, regulatory changes, and market volatility. Recent strategic moves include a joint mining agreement with an affiliate to deploy mining hardware and optimize facility utilization [S1][S2].

Alaska Silver Corp., incorporated in British Columbia in 2020, operates in the mineral exploration and development sector with a focus on Alaskan properties such as Illinois Creek, Round Top, and Honker. The company consolidates its operations through wholly owned subsidiaries in the USA. It is publicly traded on the TSX Venture Exchange under the symbol 'WAM'. The company’s financials as of March 31, 2026, show cash and equivalents of approximately $6.4 million USD and a current ratio of 1.44, indicating liquidity to support ongoing operations. Recent activities include a significant drill program at Illinois Creek and successful capital raises through offerings. The company’s financial statements comply with US GAAP and SEC regulations, and management highlights the need for further financing to continue development and exploration activities.

Transportation & Logistics Systems, Inc. is a publicly traded holding company currently without operating business, classified as a shell company. The company ceased operations in the first quarter of 2024 due to lack of capital and insolvency of subsidiaries. It is pursuing a restructuring strategy and exploring new business opportunities, including a planned acquisition of Patriot Glass Solutions, LLC, which specializes in automotive and commercial window tinting and proprietary glass strengthening technologies. The acquisition is intended to provide a profitable platform and expand TLSS's presence in the safety and security technology industry. The company faces significant financial and operational risks, including liquidity constraints, recurring losses, dilution from convertible preferred stock, and dependence on a sole executive officer. TLSS has material weaknesses in internal controls and limited management depth, impacting its ability to report financial results timely and accurately.